212 related articles for article (PubMed ID: 36640300)
1. A multiplexed in vivo approach to identify driver genes in small cell lung cancer.
Lee MC; Cai H; Murray CW; Li C; Shue YT; Andrejka L; He AL; Holzem AME; Drainas AP; Ko JH; Coles GL; Kong C; Zhu S; Zhu C; Wang J; van de Rijn M; Petrov DA; Winslow MM; Sage J
Cell Rep; 2023 Jan; 42(1):111990. PubMed ID: 36640300
[TBL] [Abstract][Full Text] [Related]
2. CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer.
Ng SR; Rideout WM; Akama-Garren EH; Bhutkar A; Mercer KL; Schenkel JM; Bronson RT; Jacks T
Proc Natl Acad Sci U S A; 2020 Jan; 117(1):513-521. PubMed ID: 31871154
[TBL] [Abstract][Full Text] [Related]
3. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
[TBL] [Abstract][Full Text] [Related]
4. Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
Udagawa H; Umemura S; Murakami I; Mimaki S; Makinoshima H; Ishii G; Miyoshi T; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuchihara K; Goto K
Lung Cancer; 2018 Dec; 126():182-188. PubMed ID: 30527185
[TBL] [Abstract][Full Text] [Related]
5. Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer.
Jin Y; Chen Y; Tang H; Hu X; Hubert SM; Li Q; Su D; Xu H; Fan Y; Yu X; Chen Q; Liu J; Hong W; Xu Y; Deng H; Zhu D; Li P; Gong Y; Xia X; Gay CM; Zhang J; Chen M
Clin Cancer Res; 2022 Feb; 28(3):526-539. PubMed ID: 34921019
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.
Umemura S; Mimaki S; Makinoshima H; Tada S; Ishii G; Ohmatsu H; Niho S; Yoh K; Matsumoto S; Takahashi A; Morise M; Nakamura Y; Ochiai A; Nagai K; Iwakawa R; Kohno T; Yokota J; Ohe Y; Esumi H; Tsuchihara K; Goto K
J Thorac Oncol; 2014 Sep; 9(9):1324-31. PubMed ID: 25122428
[TBL] [Abstract][Full Text] [Related]
7. [Comprehensive Genomic Analysis for Small Cell Lung Cancer].
Shibata Y; Udagawa H; Matsumoto S; Goto K
Gan To Kagaku Ryoho; 2021 Apr; 48(4):476-485. PubMed ID: 33976029
[TBL] [Abstract][Full Text] [Related]
8. Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer.
Udyavar AR; Hoeksema MD; Clark JE; Zou Y; Tang Z; Li Z; Li M; Chen H; Statnikov A; Shyr Y; Liebler DC; Field J; Eisenberg R; Estrada L; Massion PP; Quaranta V
BMC Syst Biol; 2013; 7 Suppl 5(Suppl 5):S1. PubMed ID: 24564859
[TBL] [Abstract][Full Text] [Related]
9. Genetically-engineered mouse models of small cell lung cancer: the next generation.
Oser MG; MacPherson D; Oliver TG; Sage J; Park KS
Oncogene; 2024 Feb; 43(7):457-469. PubMed ID: 38191672
[TBL] [Abstract][Full Text] [Related]
10. Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer.
Ciampricotti M; Karakousi T; Richards AL; Quintanal-Villalonga À; Karatza A; Caeser R; Costa EA; Allaj V; Manoj P; Spainhower KB; Kombak FE; Sanchez-Rivera FJ; Jaspers JE; Zavitsanou AM; Maddalo D; Ventura A; Rideout WM; Akama-Garren EH; Jacks T; Donoghue MTA; Sen T; Oliver TG; Poirier JT; Papagiannakopoulos T; Rudin CM
Cancer Discov; 2021 Dec; 11(12):3214-3229. PubMed ID: 34344693
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive genomic profiles of small cell lung cancer.
George J; Lim JS; Jang SJ; Cun Y; Ozretić L; Kong G; Leenders F; Lu X; Fernández-Cuesta L; Bosco G; Müller C; Dahmen I; Jahchan NS; Park KS; Yang D; Karnezis AN; Vaka D; Torres A; Wang MS; Korbel JO; Menon R; Chun SM; Kim D; Wilkerson M; Hayes N; Engelmann D; Pützer B; Bos M; Michels S; Vlasic I; Seidel D; Pinther B; Schaub P; Becker C; Altmüller J; Yokota J; Kohno T; Iwakawa R; Tsuta K; Noguchi M; Muley T; Hoffmann H; Schnabel PA; Petersen I; Chen Y; Soltermann A; Tischler V; Choi CM; Kim YH; Massion PP; Zou Y; Jovanovic D; Kontic M; Wright GM; Russell PA; Solomon B; Koch I; Lindner M; Muscarella LA; la Torre A; Field JK; Jakopovic M; Knezevic J; Castaños-Vélez E; Roz L; Pastorino U; Brustugun OT; Lund-Iversen M; Thunnissen E; Köhler J; Schuler M; Botling J; Sandelin M; Sanchez-Cespedes M; Salvesen HB; Achter V; Lang U; Bogus M; Schneider PM; Zander T; Ansén S; Hallek M; Wolf J; Vingron M; Yatabe Y; Travis WD; Nürnberg P; Reinhardt C; Perner S; Heukamp L; Büttner R; Haas SA; Brambilla E; Peifer M; Sage J; Thomas RK
Nature; 2015 Aug; 524(7563):47-53. PubMed ID: 26168399
[TBL] [Abstract][Full Text] [Related]
12. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
Peng J; Wang Q; Liu H; Ye M; Wu X; Guo L
Tumour Biol; 2016 Sep; 37(9):11959-11971. PubMed ID: 27101199
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma.
Makinoshima H; Umemura S; Suzuki A; Nakanishi H; Maruyama A; Udagawa H; Mimaki S; Matsumoto S; Niho S; Ishii G; Tsuboi M; Ochiai A; Esumi H; Sasaki T; Goto K; Tsuchihara K
Cancer Res; 2018 May; 78(9):2179-2190. PubMed ID: 29490947
[TBL] [Abstract][Full Text] [Related]
14. Cells Lacking the
Oser MG; Fonseca R; Chakraborty AA; Brough R; Spektor A; Jennings RB; Flaifel A; Novak JS; Gulati A; Buss E; Younger ST; McBrayer SK; Cowley GS; Bonal DM; Nguyen QD; Brulle-Soumare L; Taylor P; Cairo S; Ryan CJ; Pease EJ; Maratea K; Travers J; Root DE; Signoretti S; Pellman D; Ashton S; Lord CJ; Barry ST; Kaelin WG
Cancer Discov; 2019 Feb; 9(2):230-247. PubMed ID: 30373918
[TBL] [Abstract][Full Text] [Related]
15. Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations.
Krencz I; Sztankovics D; Danko T; Sebestyen A; Khoor A
Cancer Metastasis Rev; 2021 Dec; 40(4):1141-1157. PubMed ID: 34958428
[TBL] [Abstract][Full Text] [Related]
16. FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1.
Chen R; Li D; Zheng M; Chen B; Wei T; Wang Y; Li M; Huang W; Tong Q; Wang Q; Zhu Y; Fang W; Guo L; Fang S
J Cell Mol Med; 2020 Feb; 24(3):2123-2134. PubMed ID: 31957179
[TBL] [Abstract][Full Text] [Related]
17. Identification of DHODH as a therapeutic target in small cell lung cancer.
Li L; Ng SR; Colón CI; Drapkin BJ; Hsu PP; Li Z; Nabel CS; Lewis CA; Romero R; Mercer KL; Bhutkar A; Phat S; Myers DT; Muzumdar MD; Westcott PMK; Beytagh MC; Farago AF; Vander Heiden MG; Dyson NJ; Jacks T
Sci Transl Med; 2019 Nov; 11(517):. PubMed ID: 31694929
[TBL] [Abstract][Full Text] [Related]
18. Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
Augert A; Zhang Q; Bates B; Cui M; Wang X; Wildey G; Dowlati A; MacPherson D
J Thorac Oncol; 2017 Apr; 12(4):704-713. PubMed ID: 28007623
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
20. Molecular subtyping of small-cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies.
Wang H; Wu S; Li Z; Zhang C; Shang X; Zhao C; Li Z; Lin J; Guo J; Wang Z
Cancer Sci; 2023 Feb; 114(2):665-679. PubMed ID: 36178064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
